Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyloris PharmaceuticalsLTS:0AB6 +2.61%59 3-Year ROIIC % is 1,070.67 as of Dec. 2025, which is 998% above its 10-year median of 97.52. GuruFocus rates LTS:0AB6 with a GF Score™ of 59/100 and a GF Value™ of €9.35. The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Hyloris Pharmaceuticals ranks better than 94.25% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hyloris Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,070.67%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hyloris Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
LTS:0AB6's 3-Year ROIIC % is ranked better than 94.25% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs LTS:0AB6: 1070.67
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hyloris Pharmaceuticals 3-Year ROIIC % Related Terms
Hyloris Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's 3-Year ROIIC % falls into.
Hyloris Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -7.2788378 (Dec. 2025) - -11.508 (Dec. 2022) )
/
( 15.312 (Dec. 2025) - 14.917 (Dec. 2022) )
=
4.2291622
/
0.395
=
1,070.67%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hyloris Pharmaceuticals (LTS:0AB6) has a 3-Year ROIIC % of 1,070.67 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hyloris Pharmaceuticals and its competitors. This is 998% above median its historical median of 97.52. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #76 out of 1322 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Hyloris Pharmaceuticals' 3-Year ROIIC % too high?
Hyloris Pharmaceuticals' current 3-Year ROIIC % of 1,070.67 is 998% above median its 10-year median of 97.52. Based on the distribution chart, Hyloris Pharmaceuticals ranks #76 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #76 out of 1322 companies for 3-Year ROIIC %. This places Hyloris Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current 3-Year ROIIC % is 1,070.67, which is 998% above median its own 10-year median of 97.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Hyloris Pharmaceuticals (LTS:0AB6) has a current 3-Year ROIIC % of 1,070.67. The stock's GF Value™ is €9.35, compared to a current price of €4.71 — trading 49.6% below its estimated fair value. The current 3-Year ROIIC % is 1,070.67, which is 998% above median its 10-year median of 97.52. Hyloris Pharmaceuticals' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current 3-Year ROIIC % is 1,070.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.71 is trading 49.6% below its estimated GF Value™ of €9.35.
Key valuation signals for LTS:0AB6:
3-Year ROIIC %: 1,070.67 (998% above median its 10-year median of 97.52)
GF Value™: €9.35 vs. price of €4.71 (49.6% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
59GF Score
Get the complete analysis for LTS:0AB6
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
